Recently, the National Audit Office released the audit dynamics “Convening a video conference on audit rectification work, conducting public health construction project audits…” It mentioned that the Audit Bureau of Wuhan City, Hubei Province, conducted an audit of public health construction projects at the municipal level. The Audit Bureau of Wuhan City examines whether the construction projects comply with relevant plans, industrial and industry policies, whether the funds are raised in place, whether the project approval procedures are complete, and whether the projects are advanced on schedule, to promote the implementation of public health projects. Pay attention to the construction of major epidemic treatment bases at the municipal level, review the construction of negative pressure wards and negative pressure operating rooms, whether infectious disease beds, normal beds, and peacetime and wartime beds meet the planning requirements, the reserve of hemodialysis machines in designated hospitals meets the standards, whether the reserves ...
Recently, Mindray Medical disclosed the record of the investor relations event held on September 14, and answered several questions of concern to investors. Among them, “North American growth is lower than expected”, “future performance guidance targets”, mergers and acquisitions, AI medical layout and other issues have become the focus of this meeting. In this regard, Mindray Medical also answered from relevant perspectives. Among them, when mentioning future performance guidance, Mindray Medical said that based on the current situation, the company still has strong confidence that it can successfully achieve the goal of global medical device TOP20 in 2025 at the latest according to the established plan. Achieve global medical device TOP20 at the end of 2025 at the latest. According to the data, Mindray Medical mainly has three major production lines: life information and support, in vitro diagnosis and medical imaging. In recent years, it has also begun to focus ...
Henlius Biopharmaceutical Editor September 23, 2024 09:21 Shanghai H drug Hans form ® It is the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC H drug Hans form ® Expected to become the first and only anti-PD-1 monoclonal antibody marketed in Europe for first-line treatment of ES-SCLC H drug Hans form ® Currently approved for market in countries such as China, Indonesia, Cambodia, and Thailand, benefiting approximately 80000 patients On September 20, 2024, Fosun Pharma (2696. HK) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the company’s independently developed anti-PD-1 monoclonal antibody H drug, Hansid ® (Sullimumab) has received positive approval for marketing authorization, and it is recommended to approve its indication for first-line treatment of extensive stage small cell lung cancer (ES-SCLC). In 2023, Fosun Pharma partnered with Intas to grant exclusive development and commercialization rights for ...
BioArt In the brains of mammals, in addition to a large number of neurons, there are also a large number of glial cells. These glial cells are widely involved in various aspects of advanced brain functions. Among them, astrocytes, as one of the most abundant glial cells in the mammalian brain, play a crucial role in the functioning of the brain, including participating in synaptic pruning, formation of the blood-brain barrier, and regulation of brain homeostasis balance. Moreover, an increasing number of studies indicate that astrocytes are directly involved in the processing of neural circuit information, and their developmental disorders may trigger various brain diseases. It is worth noting that the morphology and transcriptome characteristics of astrocytes exhibit high heterogeneity in different brain regions and even within the same brain region. During the development of the brain, the origin of astrocytes, namely the location of neural stem cells, determines the ...
Dental equipment pioneer Henry Schein announced that it has completed the acquisition of Shield Healthcare Inc. Shield Healthcare Inc. is a device company that directly provides home care medical products to patients. Henry Schein announced this transaction last year. 01 Enters the field of household appliances In August 2023, Henry Schein announced that he had signed an agreement to acquire a majority stake in Shield Healthcare, Inc. On the basis of Henry Schein’s acquisition of Prism Medical Products LLC in 2021, Shield Healthcare will expand Henry Schein’s existing medical business by providing diversified product series, including incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes products. In addition, it will provide patients with continuous blood glucose monitoring devices directly at home. As the healthcare industry continues to shift towards home care, we have expanded our business of directly providing medical products to patients through our partnership with Shield Healthcare, ...
After Edward Life Sciences (hereinafter referred to as Edward) sold its intensive care business to Becton DickinsonMedical for $4.2 billion, a major global layoff has begun. Approximately 3% of employees will be affected by this layoff, and according to proportional calculations, about 540 employees will be laid off. Edward CEO Bernard Zovighian stated that employees affected by the global layoffs have received notice today that some employees may temporarily stay to assist with the transformation of the intensive care business, while others may find other jobs within the company. 30.4 billion yuan sale, 4500 employees join Becton Dickinson Edward is deeply engaged in the fields of global structural heart disease, intensive care, and surgical monitoring. Currently, he has multiple advanced products such as heart valves, cardiac intervention therapy equipment, cardiac monitoring equipment, and surgical tools. Among them, with the “world’s first successfully implanted artificial mitral valve”, Edward firmly occupies the ...
In the gift recovery market, the prices of An Gong Niu Huang Wan and Pian Zi Huang, which have remained strong, have begun to fall in the second half of this year. A recycling merchant from Chengdu informed reporters from Caixin, “This year’s market conditions are poor. The price of Pian Zi Huang has dropped nearly 100 yuan per pill within a year.” A recycling merchant in Beijing also noted, “Before June of this year, the price of new An Gong Niu Huang Wan was around 600-650 yuan per pill, but it has dropped significantly in recent months.” Interviews with various recycling merchants revealed that since June, second-hand market prices have noticeably decreased. Currently, the price of new Pian Zi Huang is around 550 yuan per pill, while An Gong Niu Huang Wan (Tong Ren Tang’s dual-natural version) is priced between 450 and 500 yuan per pill. Expired or near-expiry ...
As one of the blue oceans in the field of autoimmune diseases , inflammatory bowel disease (IBD) treatment drugs are sought after and deployed by many multinational pharmaceutical companies. Recently, Eli Lilly acquired Morphic for US$3.2 billion and obtained its core pipeline α4β7 integrin inhibitor MORF-057, further expanding its influence in the field of gastrointestinal diseases. In addition to Eli Lilly, pharmaceutical giants including AbbVie, AstraZeneca, and Merck have laid out IBD treatment drugs and carried out related mergers and acquisitions. Behind the frequent actions, why do multinational pharmaceutical companies favor IBD treatment drugs so much? The dilemma of traditional treatment IBD is a chronic inflammatory bowel disease that mainly affects the digestive system. Its symptoms include severe diarrhea, frequent abdominal pain, blood in the stool, weight loss, and severe cancer. IBD mainly includes two types: ulcerative colitis (UC) and Crohn’s disease (CD). The two IBDs have both overlaps and ...
On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
Recently, Sinopharm Holdings issued an announcement on changes in the composition of the board committee, and Zhao Bingxiang was appointed as a non-executive director of Sinopharm. According to the process at the end of August, “the board of directors of Sinopharm has decided to elect Zhao Bingxiang as chairman of the board of directors. This appointment must be approved by shareholders at the shareholders’ meeting before the appointment of its non-executive director can take effect.” Zhao Bingxiang’s appointment as a non-executive director of Sinopharm also means that His appointment as chairman of the state-controlled company takes effect. At present, Sinopharm’s official website and announcement information have been updated, and Zhao Bingxiang serves as the chairman, non-executive director and party committee secretary of Sinopharm Holdings. It is reported that Zhao Bingxiang has worked in the China Resources department for a long time. He has served as a senior researcher at the ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.